Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

July 6, 2018: By Jon Swedien

Opthea has enrolled 176 patients, about half its planned total, in a Phase IIb trial of its wet age-related macular degeneration (AMD) candidate, the company announced July 2.

The Melbourne, Australia, firm said it remains on track to report data from the study in early 2020.

The candidate is OPT-302, a VEGF-C/D inhibitor. The study is designed to determine if OPT-302 improves visual acuity and anatomical parameters, such as retinal fluid and thickness, in patients receiving standard of care anti-VEGF-A therapy for wet AMD.

The study will randomize patients in a 1:1:1 ratio. One group will receive OPT-302 administered at 0.5 mg in combination with Lucentis (ranibizumab, 0.5 mg). Another group will receive 2 mg of OPT-302 in combination with Lucentis. A third group will receive only Lucentis and a sham injection.

Treatments will be administered on a monthly basis for six months via intravitreal injection.

Opthea also has a Phase Ib/IIa trial for OPT-302 as a treatment candidate for diabetic macular edema.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023